O2h Ventures
VC Fund
O2h Ventures is a VC fund focused on Biotechnology and Health Care. Investment firm which in backing biotech, offering investors the opportunity to back promising medical innovations via the EIS and SEIS.
- Total investments:
- 49
- Last investment:
- Lead investor:
- 43%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries O2h Ventures invests in
Stages O2h Ventures invests in
Countries O2h Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $603k–$7.5M
- Series A
- $1.9M–$25M
- Venture - Series Unknown
- $1.1M–$2.9M
Investment Focus
Industry
- Biotechnology 24 (49%)
- Health Care 20 (41%)
- Pharmaceutical 9 (18%)
- Biopharma 7 (14%)
- Medical 6 (12%)
Stage
- Seed 17 (35%)
- Series A 5 (10%)
- Venture - Series Unknown 4 (8%)
- Pre-Seed 3 (6%)
- Funding Round 3 (6%)
Country
- United Kingdom 31 (63%)
- Hungary 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Sunil Shah
CEO & Co-Founder
|
CEO & Co-Founder | Total investments: 11 | Find email | |
Sunil Shah
CEO & Co-Founder
|
CEO & Co-Founder | Total investments: 14 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Monument Therapeutics
|
Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system. | $1.1M / Venture - Series Unknown / Feb 25, 2025 | |
Atelerix
|
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered whenneeded by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered | $933.1K / Jan 28, 2025 | |
Healx
|
Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AItechnology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact. Founded in Cambridge, UK, in 2014 by Dr Tim Guilliams (a Biochemical Engineer and tech entrepreneur) and Dr David Brown (co-inventor of Viagra and former Global Head of Drug Discovery at Roche), Healx has raised $70 million to date. For more information, visit www.healx.io. | $47M / Series C / Aug 01, 2024 | |
ViaNautis
|
Precision Solutions | $24.6M / Series A / Nov 13, 2023 | |
Pencil Biosciences
|
Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available. | $7.3M / Seed / Sep 28, 2023 | |
Kuano
|
Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates. | $2.2M / Seed / Sep 12, 2023 | |
PharmEnable
|
PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery of vital new medicines. | $7.5M / Seed / May 22, 2023 | |
Five Alarm Bio
|
Five Alarm Bio is a drug discovery company. Five Alarm intends to use discoveries to provide secure and efficient remedies for a variety of age-related illnesses and limitations. Five Alarm Bio is creating a small molecule strategy to strengthen the body's defense against aging. | $603.1K / Seed / Feb 27, 2023 | |
Qkine
|
Qkine manufactures high-purity, animal-free growth factors, cytokines and other complex proteins. Based on the Cambridge Science Park, UK, we combine proprietary protein production processes developed at the University of Cambridge with protein engineering techniques to develop unique products that tackle fundamental biological and scale-upchallenges for the fast-growing stem cell, organoid, regenerative medicine and cultivated meat sectors. Qkine has an active R&D pipeline, with a continually expanding product range. Unique products available from Qkine include tag-free thermostable FGF-2 (FGF2-G3), the first animal-free TGF beta 1 for chemically defined stem cell media, and animal-free HGF (NK1). Qkine is an ISO 9001: 2015 certified company. | $5.2M / Series B / Dec 15, 2022 | |
Alevin Therapeutics
|
Alevin Therapeutics is creating breakthrough approaches to safe and effective medicines for patients with life-threatening diseases. | Seed / Jul 29, 2022 | |
| See all 49 investments → | |||
Co-Investors
ACF Investors
7 deals together
SyndicateRoom
5 deals together
University of Cambridge Enterprise
5 deals together
Wren Capital
5 deals together
Accel
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does O2h Ventures invest in?
O2h Ventures invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 49 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is O2h Ventures's check size?
O2h Ventures typically joins rounds of $603k–$7.5M at Seed, $1.9M–$25M at Series A and $1.1M–$2.9M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds O2h Ventures participates in.
How do I contact O2h Ventures?
Public channels for O2h Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at O2h Ventures?
The team at O2h Ventures includes Sunil Shah (CEO & Co-Founder) and Sunil Shah (CEO & Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
